Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Myriad Genetics (MYGN) PT Raised to $37 at Needham & Company
February 6, 2019 8:05 AM ESTNeedham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while maintaining a Strong Buy rating.
Unger commented, "We are updating our financial model for MYGN following last night's release of FY2Q19 results. Our... More
Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook
February 5, 2019 4:31 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.38, $0.03 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $216.8 million versus the consensus estimate of $216.73 million.
"This quarter we saw a return to revenue growth for our hereditary cancer business, an... More
